Human Plasma‐Derived C1 Inhibitor for Short‐Term Prophylaxis in Hereditary Angioedema With Normal C1 Inhibitor

Key Points

• To evaluate the effectiveness of plasma-derived C1 inhibitor in preventing attacks during short-term prophylaxis in hereditary angioedema with normal C1 inhibitor.
• Administered plasma-derived C1 inhibitor to patients with hereditary angioedema with normal C1 inhibitor (HAE-nC1INH).
• Monitored the incidence of post-procedure attacks in these patients.
• Compared efficacy against patients with HAE-FXII and HAE-UNK.
• Reduced the risk of post-procedure attacks in patients with HAE-nC1INH.
• Efficacy in preventing attacks was significantly higher in patients with HAE-FXII than in those with HAE-UNK.